Oncologist-Reported Reasons for Not Ordering Multimarker Tumor Panels: Results From a Nationally Representative Survey Supported in part by the United States Department of Veterans Affairs, Veterans ...

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

For more than four decades, oncologists have known that a single protein drives nearly all pancreatic cancers, and for just ...

FDA fast-tracks VS-7375, an oral KRAS G12D inhibitor, opening new hope for pretreated advanced NSCLC and fueling pivotal ...

Laboratory Corporation of America Holdings or LabCorp LH recently announced the availability of therascreen KRAS PCR Mutation Analysis -- a companion diagnostic (CDx) to spot patients with non-small ...

Q: Should I be tested for the KRAS mutation before beginning colorectal cancer treatment? Recent research confirmed that the mutation status of the KRAS gene in colon cancer patients can determine if ...

Please provide your email address to receive an email when new articles are posted on . Less than half of patients received MSI testing and about one-quarter received KRAS testing. Older age, rural ...

The Fast Track designation is designed to help promising medicines for serious diseases reach patients faster by allowing ...

PLEASANTON, Calif., May 11, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the cobas® KRAS Mutation Test for ...

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today presented promising preclinical data from its pan-KRAS program including the novel, oral inhibitor BI 1701963 at the AACR-NCI-EORTC ...

For patients diagnosed with advanced lung cancer driven by a specific genetic flaw called KRAS G12C, the first-line treatment ...